SOPHiA DDM™ for Measurable Residual Disease (MRD)

Go beyond complete response with targeted NGS MRD analysis

Confidently detect even the smallest trace of cancer by combining the power of next-generation sequencing (NGS) and the advanced analytical capabilities of the SOPHiA DDM™ Platform.

Request a Demo

Overview Key Features Workflow Analytics Applications Resources

OVERVIEW

Accurately detect even the smallest trace of cancer

More than 50% of Acute Myeloid Leukemia (AML) patients relapse within three years after achieving complete remission.¹ The SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution utilizes targeted NGS analysis to accurately detect variants down to 0.01% variant allele frequency (VAF) for key genes linked to AML.

Get the complete MRD story

Simultaneously assess 23 ELN guideline-recommended genes to identify and track AML-associated mutations in a single sample.

The SOPHiA DDM™ RAM Solution utilizes a decentralized, platform-agnostic workflow powered by advanced analytics, enabling clinical research in MRD and accelerating breakthrough discoveries.

SOPHiA DDM™

Loum dolor sit ameectetur

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris semper dolor ut velit tristique, quis dignissim dui ullamcorper. Proin viverra leo eu ullamcorper consequat. Sed sit amet interdum est. Integer porttitor dui a augue tincidunt, ac pellentesque orci lacinia.

Praesent quis aliquam quam. Maecenas eros nulla, luctus sed leo vel, congue cursus ex. Maecenas ac erat quis felis rhoncus euismod vel a ligula. Integer urna turpis, semper ac nunc ac, iaculis vestibulum sapien. Nunc

Easily navigate complex analysis

SOPHiA DDM™ for Blood Cancers simplifies analysis of genomic drivers in hematological cancers using the trusted analytical performance and advanced features of the SOPHiA DDM™ platform.

Streamline raw genomic data analysis to precisely detect, annotate, and prioritize even the most complex blood cancer variants.

KEY FEATURES

Aim for the right targets in MRD detection

At SOPHiA GENETICS, we offer a complete portfolio of pipelines and end-to-end NGS applications (from sample to report) to fulfill your needs and better assess key biomarkers involved in myeloid and lymphoid neoplasms, and essential for detection and quantification of measurable residual disease (MRD).

KEY FEATURES

Aim for the right targets in MRD detection

Empower robust decision-making with accurate detection of key AML genomic biomarkers, streamlined variant interpretation, and simplified longitudinal monitoring.

Ultra-sensitive variant detection

Leverage our proprietary CUMIN™ molecular adaptor technology for ultrasensitive variant detection with a limit of detection (LoD) down to 0.01% VAF.

Curated gene content

Simultaneously assess and track over time 23 genes critically associated with AML according to ELN guidelines with the SOPHiA DDM™ RAM Solution. Featuring curated, high-quality gene content, it ensures comprehensive and accurate analysis to empower decision-making.

Longitudinal interface

Utilize a dedicated interface for longitudinal variant monitoring to visualize the mutational landscape and its evolution over time.

“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment. We look forward for the results of this research enabled by SOPHiA’s unique platform”
Patrick van Berkel
Sr VP of Research and Development, ADC Therapeutics
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma.”
Abasi Ene-Obong, PhD.
Founder, Syndicate Bio
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment. We look forward for the results of this research enabled by SOPHiA’s unique platform”
Patrick van Berkel
Sr VP of Research and Development, ADC Therapeutics

WORKFLOW

See what other tests might miss with NGS

Streamline your sample-to-report MRD workflow with solutions designed to enhance genomic profiling and monitoring of residual disease.

You won’t be left alone.
Enjoy comprehensive support at every step through the SOPHiA DDM™ MaxCare Program, making in-house adoption a breeze.

WORKFLOW

A wave of insights for every laboratory

Streamline your blood cancer analysis workflow from sample to comprehensive, customized report.

Flexible and scalable library preparation

Rely on robust sequencing across multiple applications using one universal and automated protocol.

Advanced variant interpretation

Match tumor molecular profiles with clinical associations and available clinical

Accurate variant detection and annotation

Precisely detect challenging genomic variants thanks to the power of our proprietary algorithms.

Customizable reporting

Quickly prepare comprehensive reports tailored to your needs.

Explore our Professional Services CTA

ANALYTICS

Enhance your MRD analysis

Expand your MRD detection capabilities with the power of NGS and the advanced analytics of the SOPHiA DDM™ Platform.

SOPHiA DDM™ enables sensitive detection of MRD markers at allele frequencies as low as 0.01% with excellent sensitivity. By incorporating our proprietary CUMIN™ unique molecular identifier (UMI) technology into sample preparation and leveraging our bioinformatic expertise, errors introduced during library preparation, target enrichment, or sequencing can be filtered out and true variant alleles identified. Moreover, precise molecule counting allows you to reliably measure the MRD signal.

Technology Principles

Our sophisticated SNV and Indel calling algorithm implements relevant analytical modules that are tailored to reduce noise linked to sample type, sequencer, and library preparation. Owing to probabilistic, molecule-based signal estimation, molecular signal and noise measurements for each individual MRD marker are provided.

Technology Principles

MRD Score

MRD Score provides a measure of the MRD signal reliability by comparing the signal of one or more selected MRD markers to the expected noise levels at the genomic position of each marker. A score of 50 or more, on a scale of 0-100, means that the signal is significantly higher than the expected background noise.

Technology Principles

Test CUMIN™: Precise molecular barcoding

SOPHiA DDM™ enables sensitive detection of clinically relevant variants at low allele frequencies (< 0.01% VAF) for MRD.

By incorporating our proprietary CUMIN™ unique molecular identifier (UMI) technology into sample preparation and leveraging our bioinformatic expertise, errors introduced during library preparation, target enrichment, or sequencing can be filtered out and true variant alleles identified.

SOPHiA DDM™ for Blood Cancers

Master the challenge of blood cancer analysis

Request a Demo

APPLICATIONS

A Portfolio of Blood Cancer Solutions

Accurately characterize the complex mutational landscape associated with major hereditary cancer disorders using one of our RUO, CE-IVD (Dx), or community solutions.

FLYER